glp-1 drugs New Guidelines for Type 2 Diabetes in 2025 What are GLP-1 medications and

Branded Saxenda sales fell to roughly $300 million in the first half of 2025 as newer GLP-1 therapies, including semaglutide and tirzepatide, gained market share

GLP-1 receptor agonists also delay gastric emptying, thereby promoting satiety

Drugs like Ozempic, Wegovy, and Mounjaro are not just treatmentsthey represent a major shift toward hormone-based, targeted therapy

subsequent preclinical studies have thus screened agonists with primates with Trp33 ECD or receptor mutants with substitution of Ser33 ECD by Trp33 ECD

HF, heart failure

The first identified enteropagin is glucose-dependent insulin-stimulating peptide (GIP)